Agile_Logo-color on white.jpg
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
October 26, 2023 08:05 ET | Agile Therapeutics, Inc.
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it...
Agile_Logo-color on white.jpg
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2023 16:30 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the granting of a previously disclosed inducement award to...
Agile_Logo-color on white.jpg
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 08:05 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari...
Agile_Logo-color on white.jpg
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023 08:05 ET | Agile Therapeutics, Inc.
Twirla Delivers Second Quarter 2023 Net Revenue of $5.5 Million, a 44% Increase from First Quarter 2023 Twirla Demand and Factory Sales Up 24% and 42% Respectively in Second Quarter 2023 Compared to...
Agile_Logo-color on white.jpg
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
July 26, 2023 08:30 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2023 financial results before...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
June 26, 2023 08:01 ET | Agile Therapeutics, Inc.
Twirla (levonorgestrel and ethinyl estradiol) transdermal system will be made available nationwide to members of MMCAP Infuse, effective July 1, 2023 MMCAP Infuse has over 26,000 member facilities...
Agile_Logo-color on white.jpg
Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
June 23, 2023 12:05 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today praised the Executive Order issued by President Biden that addresses...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
June 15, 2023 16:05 ET | Agile Therapeutics, Inc.
FPA Women’s Health is the largest independent family planning service network in the United States, and the Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now the exclusive patch...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
June 13, 2023 16:05 ET | Agile Therapeutics, Inc.
Agile Plans to Increase Twirla prescriptions filled through telemedicine platforms that utilize vitaCare, such as Twentyeight Health™ Partnership Expected to Augment Future Growth in the Retail...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
May 25, 2023 16:05 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its...